Ligon, Keith L.

Machine learning for cryosection pathology predicts the 2021 WHO classification of glioma

Nasrallah, M. P., Zhao, J., Tsai, C. C., Meredith, D., Marostica, E., Ligon, K. L., Golden, J. A., & Yu, K.-H. (2023) · Med

AI in cancer detectionGlioma Diagnosis and Treatment

Cited by 67

Rates and Patterns of Clonal Oncogenic Mutations in the Normal Human Brain

Ganz, J., Maury, E. A., Becerra, B., Bizzotto, S., Doan, R. N., Kenny, C. J., Shin, T., Kim, J., Zhou, Z., Ligon, K. L., et al. (2022) · Cancer Discovery

Cancer Genomics and DiagnosticsGlioma Diagnosis and Treatment

Cited by 48

VRK1 as a synthetic lethal target in VRK2 promoter-methylated cancers of the nervous system

So, J., Mabe, N. W., Englinger, B., Chow, K.-H., Moyer, S. M., Yerrum, S., Trissal, M. C., Marques, J. G., Kwon, J. J., Shim, B., et al. (2022) · JCI Insight

Glioma Diagnosis and TreatmentChromatin Remodeling and Cancer

Cited by 45

Tie2-FGFR1 interaction induces adaptive PI3K inhibitor resistance by upregulating Aurora A/PLK1/CDK1 signaling in glioblastoma.

Li, X., Martinez-Ledesma, E., Zhang, C., Gao, F., Zheng, S., Ding, J., Wu, S., Nguyen, N., Clifford, S. C., Wen, P. Y., et al. (2019) · Cancer Research

Glioma Diagnosis and TreatmentPI3K/AKT/mTOR signaling in cancer

Cited by 27

A window-of-opportunity trial reveals mechanisms of response and resistance to navtemadlin in patients with recurrent glioblastoma

Rendo, V., Lee, E. Q., Bossi, C., Khuu, N., Rudek, M. A., Pal, S., Azazmeh, N., Rashid, R., Lin, J.-R., Cusick, M., et al. (2025) · Science Translational Medicine

Glioma Diagnosis and TreatmentCancer-related Molecular Pathways

Cited by 19

Preclinical Modeling of Navtemadlin Pharmacokinetics, Pharmacodynamics, and Efficacy in IDH–Wild-type Glioblastoma

Vaubel, R. A., Zhang, W., Oh, J.-H., Mladek, A. C., Pasa, T. I., Gantchev, J. K., Waller, K. L., Baquer, G., Stopka, S. A., Regan, M. S., et al. (2025) · Clinical Cancer Research

Glioma Diagnosis and TreatmentCancer-related Molecular Pathways

Cited by 2